Aflac (AFL) Q4 2025 earnings review
Sales Surge in Japan, But Investment Income Drags Results
Aflac delivered a mixed Q4. The operational story is improving significantly: Japan sales surged 16% YoY driven by the new 'Miraito' cancer product, and U.S. sales grew 3%. However, financials were dampened by a changing macro environment. Adjusted earnings fell 5.4% to $818M as net investment income dropped due to lower floating rates and a weaker yen. While buybacks kept Adjusted EPS flat (+0.6%), the U.S. segment saw notable margin compression (down 230 bps). Management signaled confidence with a 5.2% dividend hike, but the earnings engine is currently relying heavily on capital engineering rather than organic profit growth.
🐂 Bull Case
Japan new annualized premium sales jumped 15.7% YoY, confirming the success of the 'Miraito' cancer product. This double-digit growth is critical for eventually reversing the long-term decline in net earned premiums.
U.S. Net Earned Premiums grew 4.0%, supported by strong persistency (79.2%). This indicates the underlying book of business is stabilizing and growing, even if margins faced a quarterly hiccup.
🐻 Bear Case
U.S. Pretax Adjusted Profit Margin fell sharply to 17.4% from 19.7% a year ago. Management cited higher benefits and expenses, raising concerns about the cost of growth initiatives and normalizing claims utilization.
Adjusted Net Investment Income fell 4.4% in Q4 (and 5.1% in the Japan portfolio). As global interest rates stabilize or fall, the floating-rate portfolio is turning from a tailwind into a headwind.
⚖️ Verdict: ⚪
Neutral. The sales turnaround in Japan is real and impressive, but the deterioration in U.S. margins and the drag from investment income are concerning. The stock is supported by aggressive buybacks ($3.5B in 2025) and dividend growth, but organic earnings growth is currently elusive.
Key Themes
Japan Sales Acceleration ('Miraito')
Accelerating. Japan sales growth of 15.7% in Q4 (vs 9% in 24Q4) validates the 'Miraito' product launch. Management noted strong sales of this cancer product and the 'Tsumitasu' first-sector product. This is the third consecutive quarter of double-digit sales growth, suggesting a durable turnaround in distribution productivity.
U.S. Margin Deterioration
Decelerating. Aflac U.S. pretax adjusted earnings fell 9.1% despite a 3.3% rise in revenues. The profit margin collapsed to 17.4% from 19.7% last year. While sales are growing (+3.1%), the cost of that growth—combined with 'higher benefits'—is eating into profitability faster than revenue is arriving.
Japan Premium Runoff Persists
Negative/Stable. Despite the sales boom, Japan Net Earned Premiums (Yen) still declined 1.9% YoY. While this is an improvement from the ~5% declines seen earlier in the year, the 'bucket' is still leaking faster than new sales can fill it due to limited-pay products reaching paid-up status. The crossover to growth remains elusive.
Investment Income Compression
Reversing. After being a tailwind, Adjusted Net Investment Income has turned negative, dropping 4.2% YoY in Q4. Specifically, the Japan segment saw a 3.9% drop in Yen terms due to lower floating rate income on the dollar portfolio. With global rates likely peaking or falling, this line item will face continued pressure.
Capital Return Intensity
Stable/High. Aflac repurchased $800M in shares in Q4 and $3.5B for the full year. Combined with dividends, the company is returning substantially all of its earnings to shareholders. This financial engineering is the primary reason Adjusted EPS (+0.6%) didn't follow Adjusted Earnings (-5.4%) into negative territory.
Other KPIs
Stable (+0.6% YoY). Saved by share count reduction (down 5.9% YoY). Actual Adjusted Earnings dollars fell 5.4%. Currency had no impact on EPS growth this quarter.
Stable (vs 31.6% in 24Q4). Despite the expense of ramping up sales (+16%), Japan maintained robust profitability, significantly higher than the U.S. segment.
Accelerating. Up 13% YoY. Benefited from an $8.0 billion cumulative increase from discount rate assumption changes on insurance reserves, offsetting foreign currency translation losses.
Guidance
Accelerating. Represents a 5.2% increase over the prior quarter. This marks the 43rd consecutive year of dividend increases, reinforcing the 'dividend aristocrat' narrative despite earnings volatility.
Stable. Management reiterated intent to 'continue balanced approach' of investing in growth and driving efficiencies. With $114.3 million shares remaining authorized for repurchase (approx. $6-7B at current prices), the buyback pace of ~$800M/quarter appears sustainable.
Key Questions
U.S. Margin Compression Structural or One-Off?
U.S. margins collapsed 230bps to 17.4% due to 'higher benefits and expenses.' Was this a specific claim spike (e.g., flu/respiratory) or a structural reset of the expense base required to generate the 3.1% sales growth?
Japan Premium Inflection Point
With sales up double-digits for three quarters, Japan Net Earned Premium decline has narrowed to -1.9%. When specifically does management model the 'crossover' point where new sales finally outweigh runoff and premiums return to growth?
Impact of Lower Rates on 2026 NII
With Adjusted Net Investment Income already down 4.4% in Q4, what is the sensitivity to further rate cuts in 2026, particularly for the floating rate portfolio which has transitioned from a tailwind to a headwind?